Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cirrhosis
Biotech
Gilead pays $4.3B for CymaBay's late-stage liver disease med
Gilead is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay, specifically for the liver disease med seladelpar.
Annalee Armstrong
Feb 12, 2024 9:01am
Akero sinks as midphase cirrhosis fail sparks flash NASH crash
Oct 10, 2023 8:00am
Galecto cans lung fibrosis med after ph. 2 fail, pivots to liver
Aug 15, 2023 7:30am
Novartis bets $80M on Pliant's preclinical NASH prospect
Oct 23, 2019 8:00am
Synlogic scraps ammonia-lowering drug after early phase fail
Aug 20, 2019 8:08am
Galectin plunges on NASH cirrhosis midstage miss
Dec 5, 2017 9:40pm